MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-18-2026
Charles River Laboratories International Depreciation & Amortization 2011-2026 | CRL
Annual Depreciation & Amortization Charles River Laboratories International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 403 M | 362 M | 314 M | 304 M | 266 M | 235 M | 198 M | 162 M | 131 M | 127 M | 94.9 M | 96.4 M | 96.6 M | 81.3 M | 85.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 403 M | 81.3 M | 197 M |
Quarterly Depreciation & Amortization Charles River Laboratories International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.2 M | 120 M | 120 M | - | 88.2 M | 86.1 M | 85.4 M | - | 78.9 M | 77.7 M | 77.1 M | - | 74.6 M | 76.4 M | 75.3 M | - | 68.7 M | 68.1 M | 61.5 M | - | 59.6 M | 57.2 M | 57.3 M | - | 51.8 M | 49.1 M | 45.4 M | - | 43.6 M | 43.4 M | 33.2 M | - | 33.5 M | 31.8 M | 32.4 M | - | 34.1 M | 32.4 M | 24.7 M | - | 23.8 M | 23.1 M | 22.4 M | - | 26.1 M | 24.3 M | 20 M | - | 67.3 M | 40.4 M | 20 M | - | 60.6 M | 40.1 M | 20 M | - | 64.2 M | 43.1 M | 21.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 120 M | 20 M | 53.1 M |
Depreciation & Amortization of other stocks in the Diagnostics research industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
321 M | $ 118.25 | -1.27 % | $ 35.9 B |  USA |
 |
Burning Rock Biotech Limited
BNR
|
47.8 M | $ 22.5 | 9.44 % | $ 242 M |  China |
 |
Accelerate Diagnostics
AXDX
|
1.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
112 K | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
1.66 M | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
161 K | - | - | $ 9.42 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
2.55 M | - | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
15 M | $ 22.42 | 27.6 % | $ 1.19 B | USA |
 |
DermTech
DMTK
|
200 K | - | -11.32 % | $ 2.94 M | USA |
 |
Akumin
AKU
|
98.2 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
1.27 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
1.11 M | $ 1.46 | 2.82 % | $ 1.94 M | USA |
 |
Exact Sciences Corporation
EXAS
|
125 M | - | - | $ 19.8 B | USA |
 |
Castle Biosciences
CSTL
|
16 M | $ 24.56 | -0.24 % | $ 682 M | USA |
 |
Global Cord Blood Corporation
CO
|
43.3 M | - | - | $ 399 M | China |
 |
Danaher Corporation
DHR
|
750 M | $ 193.78 | -2.18 % | $ 138 B | USA |
 |
Interpace Biosciences
IDXG
|
425 K | $ 2.2 | - | $ 9.73 M | USA |
 |
Heska Corporation
HSKA
|
14 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
587 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
354 M | $ 132.72 | 0.35 % | $ 21.1 B | USA |
 |
Fulgent Genetics
FLGT
|
24.9 M | $ 16.13 | -0.25 % | $ 488 M | USA |
 |
Medpace Holdings
MEDP
|
27.2 M | $ 515.65 | -0.56 % | $ 14.9 B | USA |
 |
Guardant Health
GH
|
39.7 M | $ 85.7 | 0.99 % | $ 10.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
194 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
38.3 K | $ 2.83 | -3.41 % | $ 91.8 K | USA |
 |
Biomerica
BMRA
|
87 K | $ 2.2 | 4.27 % | $ 5.05 M | USA |
 |
Motus GI Holdings
MOTS
|
451 K | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
488 M | $ 115.58 | -0.79 % | $ 9.53 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
681 M | $ 266.36 | -0.14 % | $ 22.2 B | USA |
 |
Celcuity
CELC
|
167 K | $ 125.25 | 1.44 % | $ 5.86 B | USA |
 |
Lantheus Holdings
LNTH
|
70.1 M | $ 83.92 | -0.02 % | $ 5.66 B | USA |
 |
Myriad Genetics
MYGN
|
53.7 M | $ 5.0 | -3.66 % | $ 463 M | USA |
 |
NeoGenomics
NEO
|
36.1 M | $ 8.16 | -5.99 % | $ 1.05 B | USA |
 |
Neogen Corporation
NEOG
|
119 M | $ 9.24 | -1.91 % | $ 2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
570 M | $ 191.46 | 0.02 % | $ 21.3 B | USA |
 |
ENDRA Life Sciences
NDRA
|
44 K | $ 5.17 | 0.58 % | $ 4.07 M | USA |
 |
National Research Corporation
NRC
|
7.62 M | $ 17.62 | -1.23 % | $ 394 M | USA |
 |
Invitae Corporation
NVTA
|
142 M | - | - | $ 21.2 M | USA |
 |
Natera
NTRA
|
16.7 M | $ 196.11 | -5.35 % | $ 19.3 B | USA |
 |
Organovo Holdings
ONVO
|
266 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
175 K | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
405 M | - | -0.91 % | $ 14.7 B | USA |